EUVIMEDEUVIMED entdecken
Crossref

Histidine as a Bridge: Fabricating pH-Sensitive and Target-Specific Hyaluronic Acid Nanoparticles via ZIF-8 for Drug Delivery

Yulong Yan, Jing Shi, Zhenqiao Zheng, Xiaojing Shi iD, Xubo Zhao iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Yulong Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Hyaluronic Acid, Histidine, Nanoparticles, Imidazoles. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The self-assembly of hyaluronic acid (HA) into stable nanoassemblies remains a significant challenge. To address this, we report a novel strategy utilizing l -histidine (His) as a molecular bridge to integrate HA with a zeolitic imidazolate framework-8 (ZIF-8). The key to this approach is the covalent conjugation of His to the HA backbone, which enables Zn 2+ from ZIF-8 to coordinate with the imidazole groups of His. This coordination facilitates the ZIF-8-induced assembly of HA into stable hybrid nanoparticles (HA-His/ZIF-8 NPs). The resulting system synergistically combines the CD44-targeting capability of HA with the pH-responsive dissociation of ZIF-8. These NPs demonstrated a high doxorubicin (DOX) loading capacity (0.34 mg/mg) and encapsulation efficiency (76.8%). Importantly, they exhibited controlled drug release with significant pH-dependency, achieving a cumulative release of 50.2% under weakly acidic conditions (pH 5.0) compared to only 12.4% at physiological pH (7.4). In vitro studies confirmed the target-specificity of the DOX-loaded HA-His/ZIF-8 NPs, which were efficiently internalized by CD44-positive MKN-45 gastric cancer cells via receptor-mediated endocytosis, leading to a potent cytotoxic effect (IC 50 = 1.71 μg•mL –1 ). In contrast, the efficacy was significantly lower in CD44-negative SNU-216 cells (IC 50 = 5.22 μg•mL –1 ). This work highlights the strategic use of His as a bridge to create a synergistic HA-ZIF-8 platform, offering a powerful and promising approach to the targeted therapy of CD44-overexpressing cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronic AcidHistidineNanoparticlesImidazolesDrug Delivery SystemsZeolitesHydrogen-Ion ConcentrationDoxorubicinHumansCell Line, TumorHyaluronan ReceptorsDrug LiberationDrug CarriersMetal-Organic Frameworks

Stichwörter der Autor:innen

ZIF-8drug deliveryhistidinehyaluronic acidpH-responsive

Substanzen

Hyaluronic AcidHistidineDoxorubicinImidazolesHyaluronan ReceptorsZeolitesZIF-8 metal-organic frameworkDrug CarriersMetal-Organic Frameworks

Autor:innen und Institutionen

  • College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
  • State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Laboratory Animal Center, Zhengzhou U…

ORCID-Profile: Xiaojing Shi, Xubo Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yan, Y., Shi, J., Zheng, Z., Shi, X., & Zhao, X. (2026). Histidine as a Bridge: Fabricating pH-Sensitive and Target-Specific Hyaluronic Acid Nanoparticles via ZIF-8 for Drug Delivery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01735

Vancouver

Yan Y, Shi J, Zheng Z, Shi X, Zhao X. Histidine as a Bridge: Fabricating pH-Sensitive and Target-Specific Hyaluronic Acid Nanoparticles via ZIF-8 for Drug Delivery. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01735

BibTeX
@article{Yan2026,
  author = {Yan, Yulong and Shi, Jing and Zheng, Zhenqiao and Shi, Xiaojing and Zhao, Xubo},
  title = {Histidine as a Bridge: Fabricating pH-Sensitive and Target-Specific Hyaluronic Acid Nanoparticles via ZIF-8 for Drug Delivery},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01735}
}
Kostenlos starten →